

## SMALL HOLDINGS SALE FACILITY

### PERTH, Australia and SAN FRANCISCO, California – 2 August 2024

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) today announces that it has completed the Small Shareholding Sale Facility (**Facility**) for shareholders who hold less than A\$500 of fully paid, ordinary shares in the Company (**Shares**), (**Small Shareholdings**), as announced to the ASX on 24 May 2024.

The Company provided the Facility to eligible PYC shareholders to sell their Small Shareholdings without having to act through a broker or incurring any brokerage or handling fees.

Based on the price of Shares at the close of trading on Friday, 12 July 2024, (**Closing Time**) of A\$0.13, a holding of less than 3,846 Shares constituted a Small Shareholding, making 275 shareholders eligible to participate in the facility.

The final number of shares sold under the facility was 278,542 Shares comprising 206 shareholders, which represents approximately 75% of eligible shareholders. The Shares were sold on market by Euroz Hartleys at an average price of A\$0.105 per share.

Payment was dispatched to participating shareholders on 1 August 2024.

This announcement was approved for release by the Board of PYC Therapeutics Limited.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood (Retinitis Pigmentosa type 11) into human trials. The Company is progressing a

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>

second drug program targeting a blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and early 2025 respectively.

For more information, visit [pyctx.com](http://pyctx.com), or follow us on LinkedIn and Twitter.

### **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

### **CONTACTS:**

**INVESTORS and MEDIA**  
[info@pyctx.com](mailto:info@pyctx.com)